Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mauricio Velez

Advanced Heart Failure and Transplant Cardiology Orlando, FL Medical Doctor

NPI 1780629253 CMS profile 35578

2415 N Orange Ave, Suite 700, Orlando, FL 32804

Open in the dashboard

General payments

$6,404

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$32,544 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Mauricio Velez of Orlando, FL is reported in the CMS Open Payments database as having received $6,404 across 166 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,544 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 47th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $635 16
2024 General $340 7
2023 General $580 15
2022 General $1,065 47
2021 General $1,194 36
2020 General $1,011 29
2019 General $1,578 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mauricio Velez
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Mauricio Velez were reported at $635. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Mauricio Velez Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $1,578 $863 $224–$4,562 $163
2020 $1,011 $452 $122–$3,992 $114
2021 $1,194 $550 $159–$3,571 $132
2022 $1,065 $729 $221–$4,357 $149
2023 $580 $1,002 $309–$5,827 $160
2024 $340 $931 $273–$5,204 $164
2025 $635 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,181 59 payments
  2. Abiomed $1,585 14 payments
  3. Novartis Pharmaceuticals Corporation $846 56 payments
  4. Biosense Webster, Inc. $383 10 payments
  5. Edwards Lifesciences Corporation $262 2 payments
  6. Boston Scientific Corporation $206 5 payments
  7. Medtronic, Inc. $175 2 payments
  8. Impulse Dynamics (USA) Inc. $171 2 payments
  9. Cardiva Medical, Inc. $115 2 payments
  10. Biotronik Inc. $108 1 payment
  11. Other $371 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,985 160 payments
  2. Travel and Lodging $353 4 payments
  3. Education $67 2 payments
Products named General payments · program years 2019–2025
  1. Impella $1,585 14 payments
  2. ENTRESTO $697 48 payments
  3. CardioMEMS HF System $519 17 payments
  4. CARDIOMEMS $454 14 payments
  5. LEQVIO $406 30 payments
  6. Carto 3 $383 10 payments
  7. Mitra Clip system $320 2 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $262 2 payments
  9. HeartMate 3 Left Ventricular Dev $175 5 payments
  10. WATCHMAN Access System $171 3 payments
  11. Other $1,750 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,107

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$750,544

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

28.4%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 238 $300,611
Jardiance Empagliflozin Brand 134 $155,394
Farxiga Dapagliflozin Propanediol Brand 113 $140,551
Eliquis Apixaban Brand 65 $95,084
Xarelto Rivaroxaban Brand 17 $24,960
Tacrolimus Generic 24 $8,784
Torsemide Generic 144 $4,985
Metoprolol Succinate Generic 175 $2,474
Carvedilol Generic 157 $1,879
Isosorbide Dinitrate Generic 22 $1,769

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$112,700

Medicare's payments for the services billed

Medicare patients

242

Average age 72

Services billed

1,296

88 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 71%
Chronic kidney disease 69%
Atrial fibrillation 59%
Diabetes 49%
Arthritis 47%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $28
$28 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $10
$10 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $10
$10 238 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record